VisionGate

The core of VisionGate's offering is its proprietary Cell-CT™ platform, an automated 3D single-cell imaging and analysis technology. This platform performs what is essentially an optical computed tomography scan of individual cells, using visible light to create high-resolution 3D images without harmful radiation. The system analyzes these images with advanced AI algorithms to measure hundreds of structural biomarkers, identifying abnormal and precancerous cells with a high degree of accuracy. The technology is designed to detect subtle morphological changes that are beyond the capabilities of human visual perception.

The company's lead diagnostic product, the LuCED® lung test, is a non-invasive liquid biopsy test designed for the early detection of lung cancer. The process involves a physician-ordered, take-home kit for collecting sputum (phlegm) samples over three days. These samples are then processed on the Cell-CT platform to identify malignant cells. The LuCED test aims to serve as an adjunctive tool for low-dose CT scans, helping to manage false-positive results and assess indeterminate pulmonary nodules. Blinded clinical studies have shown the test to have high sensitivity and specificity for detecting lung cancer across all stages. Beyond diagnostics, VisionGate is also developing a pharmaceutical component. The company holds rights to iloprost, an oral drug in clinical development for treating precancerous bronchial dysplasia, with the LuCED test serving as its companion diagnostic.